Literature DB >> 19513551

The expression and role of serum response factor in papillary carcinoma of the thyroid.

Hee Jin Kim1, Kyung Ryoul Kim, Ho Sung Park, Kyu Yun Jang, Myoung Ja Chung, Minho Shong, Woo Sung Moon.   

Abstract

Serum response factor (SRF) is a transcription factor of the MADS box family. SRF is involved in various cellular processes such as expression of immediate early and tissue-specific genes, cell proliferation, differentiation and apoptosis. The expression of SRF in papillary thyroid carcinoma (PTC) and its role have not been investigated, forming the basis for this study. Surgical specimens of 63 conventional PTCs along with 30 follicular adenoma, 30 adenomatous hyperplasia and 9 anaplastic carcinoma specimens were obtained from the surgical archives. The expression of SRF was determined by the use of immunohistochemical staining. We also investigated the expression level of SRF and an SRF target gene, c-fos in fresh PTC tissues and thyroid cancer cell lines (NPA, FRO and ARO) by Western blot analyses. In addition, we examined the role of SRF in PTC by overexpresion of SRF in the NPA cell line. SRF was mainly expressed in cancer cells, showing a strong nuclear and/or cytoplasmic staining in PTC. SRF was expressed in 50 of 63 cases of papillary carcinoma (79%), 18 of 30 cases of follicular adenoma (60%), 10 of 30 cases of nodular hyperplasia (33%) and 6 of 9 cases of anaplastic carcinoma (67%). The expression level of SRF was significantly up-regulated in PTC (combined staining score of 5.21+/-0.43) and anaplastic carcinoma (5.67+/-1.45) compared to that of follicular adenoma (2.30+/-0.44) (P<0.001), or adenomatous goiter (1.13+/-0.28) (P<0.001). Western blot analyses showed an increased expression of the spliced form of SRF protein and c-Fos protein in PTC as compared to non-tumor thyroid tissues. SRF expression correlated with the tumor size of the PTCs (P<0.05). Overexpression of SRF in papillary carcinoma cells enhanced cell motility and invasiveness. Our results indicate that the altered expression of SRF in papillary carcinoma cells may play an important role in PTC carcinogenesis and progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19513551

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  Androgen-responsive serum response factor target genes regulate prostate cancer cell migration.

Authors:  Alissa R Verone; Kelly Duncan; Alejandro Godoy; Neelu Yadav; Andrei Bakin; Shahriar Koochekpour; Jian-Ping Jin; Hannelore V Heemers
Journal:  Carcinogenesis       Date:  2013-04-10       Impact factor: 4.944

2.  Expression of p114RhoGEF predicts lymph node metastasis and poor survival of squamous-cell lung carcinoma patients.

Authors:  Chengyang Song; Ying Gao; Ye Tian; Xu Han; Yong Chen; Da-Li Tian
Journal:  Tumour Biol       Date:  2013-03-20

3.  Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk.

Authors:  Gisella Figlioli; Bowang Chen; Rossella Elisei; Cristina Romei; Chiara Campo; Monica Cipollini; Alfonso Cristaudo; Franco Bambi; Elisa Paolicchi; Per Hoffmann; Stefan Herms; Michał Kalemba; Dorota Kula; Susana Pastor; Ricard Marcos; Antonia Velázquez; Barbara Jarząb; Stefano Landi; Kari Hemminki; Federica Gemignani; Asta Försti
Journal:  Sci Rep       Date:  2015-03-10       Impact factor: 4.379

4.  Serum response factor is overexpressed in esophageal squamous cell carcinoma and promotes Eca-109 cell proliferation and invasion.

Authors:  Xi He; Hong Xu; Min Zhao; Shijie Wang
Journal:  Oncol Lett       Date:  2013-01-09       Impact factor: 2.967

5.  The Immune Interplay between Thyroid Papillary Carcinoma and Hepatic Fibrosis.

Authors:  Nidal Muhanna; Johnny Amer; Ahmad Salhab; Jean-Yves Sichel; Rifaat Safadi
Journal:  PLoS One       Date:  2015-07-07       Impact factor: 3.240

6.  Clinical Significance and Potential Regulatory Mechanisms of Serum Response Factor in 1118 Cases of Thyroid Cancer Based on Gene Chip and RNA-Sequencing Data.

Authors:  Qiang-Bin Jing; Hai-Xiao Tong; Wei-Jian Tang; Shao-Dong Tian
Journal:  Med Sci Monit       Date:  2020-01-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.